pcc Practice Builder™ Emerges as a Growth Engine for Medical Practices in 2026 
Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
LEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy
LX2006 is the first investigational gene therapy for the treatment of Friedreich’s ataxia cardiomyopathy Initial data from the first two...
Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs
Lugano, Switzerland, June, 12, 2023 - Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of...
Chiesi USA Partners with Smith Anderson to Host 1L Excellence in Diversity Fellow this Summer
Duke University School of Law student Cecilia Poston will work alongside Chiesi’s legal team to support her early career development...
SomaLogic Partners with Citogen to Expand Authorized Site Program in Europe
SomaLogic’s 7,000-plex SomaScan® Platform will be used in clinical research, population health studies and nutrigenomics.BOULDER, Colo., June 12, 2023 (GLOBE...
Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment
- Funding in place to meet next regulatory milestone BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT),...
Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy
The Company expands technology for patients with obsessive-compulsive disorderMALVERN, Pa., June 12, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM),...
AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments
Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of...
NeuroOne® Submits 510(k) Application to FDA for OneRF™ Ablation System
Potential for transformative improvement in neurosurgery as first known sEEG-guided RF system that records and ablates nervous tissue with the...
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
Webcast scheduled for Thursday, June 15 at 8:30am PTIRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:...
IMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy Option at the Mass General Brigham World Medical Innovation Forum 2023
Dr. Corinne Le Goff will highlight the breakthrough potential of IMNN-001 for the treatment of ovarian cancer during a panel...
Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference
BASKING RIDGE, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
Fremont, C, June 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical...
Oncotelic Launches PR Chatbot
AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”),...
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023Combined launch of vonoprazan for Erosive GERD and H....
Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed;...
Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics
The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders Professors Einar Stefánsson, and Thorsteinn...
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and responseSALT LAKE CITY, June 12, 2023...
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism
This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel...
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care agent lenalidomideHOUSTON, June 12, 2023...